| 1. |
- Kehoe, Laura, et al.
(författare)
-
Make EU trade with Brazil sustainable
- 2019
-
Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 364:6438, s. 341-
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 2. |
- Kirschenbaum, Daniel, et al.
(författare)
-
Whole-brain microscopy reveals distinct temporal and spatial efficacy of anti-A beta therapies
- 2023
-
Ingår i: EMBO Molecular Medicine. - : WILEY. - 1757-4676 .- 1757-4684. ; 15
-
Tidskriftsartikel (refereegranskat)abstract
- Many efforts targeting amyloid-beta (A beta) plaques for the treatment of Alzheimers Disease thus far have resulted in failures during clinical trials. Regional and temporal heterogeneity of efficacy and dependence on plaque maturity may have contributed to these disappointing outcomes. In this study, we mapped the regional and temporal specificity of various anti-A beta treatments through high-resolution light-sheet imaging of electrophoretically cleared brains. We assessed the effect on amyloid plaque formation and growth in Thy1-APP/PS1 mice subjected to beta-secretase inhibitors, polythiophenes, or anti-A beta antibodies. Each treatment showed unique spatiotemporal A beta clearance, with polythiophenes emerging as a potent anti-A beta compound. Furthermore, aligning with a spatial-transcriptomic atlas revealed transcripts that correlate with the efficacy of each A beta therapy. As observed in this study, there is a striking dependence of specific treatments on the location and maturity of A beta plaques. This may also contribute to the clinical trial failures of A beta-therapies, suggesting that combinatorial regimens may be significantly more effective in clearing amyloid deposition.
|
|
| 3. |
- Ni, Ruiqing, et al.
(författare)
-
Multiscale optical and optoacoustic imaging of amyloid-beta deposits in mice
- 2022
-
Ingår i: Nature Biomedical Engineering. - : NATURE PORTFOLIO. - 2157-846X. ; 6, s. 1031-1044
-
Tidskriftsartikel (refereegranskat)abstract
- Large-field multifocal illumination fluorescence microscopy and panoramic volumetric multispectral optoacoustic tomography can be combined to longitudinally assess amyloid-beta deposits in transgenic mouse models of Alzheimers disease. Deposits of amyloid-beta (A beta) in the brains of rodents can be analysed by invasive intravital microscopy on a submillimetre scale, or via whole-brain images from modalities lacking the resolution or molecular specificity to accurately characterize A beta pathologies. Here we show that large-field multifocal illumination fluorescence microscopy and panoramic volumetric multispectral optoacoustic tomography can be combined to longitudinally assess A beta deposits in transgenic mouse models of Alzheimers disease. We used fluorescent A beta-targeted probes (the luminescent conjugated oligothiophene HS-169 and the oxazine-derivative AOI987) to transcranially detect A beta deposits in the cortex of APP/PS1 and arcA beta mice with single-plaque resolution (8 mu m) and across the whole brain (including the hippocampus and the thalamus, which are inaccessible by conventional intravital microscopy) at sub-150 mu m resolutions. Two-photon microscopy, light-sheet microscopy and immunohistochemistry of brain-tissue sections confirmed the specificity and regional distributions of the deposits. High-resolution multiscale optical and optoacoustic imaging of A beta deposits across the entire brain in rodents thus facilitates the in vivo study of A beta accumulation by brain region and by animal age and strain.
|
|
| 4. |
- Zarb, Yvette, et al.
(författare)
-
Ossified blood vessels in primary familial brain calcification elicit a neurotoxic astrocyte response
- 2019
-
Ingår i: Brain. - : OXFORD UNIV PRESS. - 0006-8950 .- 1460-2156. ; 142:4, s. 885-902
-
Tidskriftsartikel (refereegranskat)abstract
- Brain calcifications are commonly detected in aged individuals and accompany numerous brain diseases, but their functional importance is not understood. In cases of primary familial brain calcification, an autosomally inherited neuropsychiatric disorder, the presence of bilateral brain calcifications in the absence of secondary causes of brain calcification is a diagnostic criterion. To date, mutations in five genes including solute carrier 20 member 2 (SLC20A2), xenotropic and polytropic retrovirus receptor 1 (XPR1), myogenesis regulating glycosidase (MYORG), platelet-derived growth factor B (PDGFB) and platelet-derived growth factor receptor beta (PDGFRB), are considered causal. Previously, we have reported that mutations in PDGFB in humans are associated with primary familial brain calcification, and mice hypomorphic for PDGFB (Pdgfb(ret/ret)) present with brain vessel calcifications in the deep regions of the brain that increase with age, mimicking the pathology observed in human mutation carriers. In this study, we characterize the cellular environment surrounding calcifications in Pdgfb(ret/ret) animals and show that cells around vessel-associated calcifications express markers for osteoblasts, osteoclasts and osteocytes, and that bone matrix proteins are present in vessel-associated calcifications. Additionally, we also demonstrate the osteogenic environment around brain calcifications in genetically confirmed primary familial brain calcification cases. We show that calcifications cause oxidative stress in astrocytes and evoke expression of neurotoxic astrocyte markers. Similar to previously reported human primary familial brain calcification cases, we describe high interindividual variation in calcification load in Pdgfb(ret/ret) animals, as assessed by ex vivo and in vivo quantification of calcifications. We also report that serum of Pdgfb(ret/ret) animals does not differ in calcification propensity from control animals and that vessel calcification occurs only in the brains of Pdgfb(ret/ret) animals. Notably, ossification of vessels and astrocytic neurotoxic response is associated with specific behavioural and cognitive alterations, some of which are associated with primary familial brain calcification in a subset of patients.
|
|
